Stock Soars: Xeris Raises Revenue Forecast to $202M Amid 100%+ Sales Surge in Blockbuster Drug
Here's a LinkedIn teaser for the article:"What drives a biopharma company to revise its revenue forecast upwards? For Xeris Biopharma Holdings, it's the remarkable triple-digit sales growth of its cortisol-inhibiting medication, Recorlev, and nearly 30% revenue growth of its emergency glucagon injection, Gvoke. As the company reports a strong Q3 performance, CEO John Shannon is optimistic about the future, with a revised revenue forecast of $198-$202 million. Learn more about Xeris' growth strategy and the factors driving its success."Read more: https://chicagopulselive.com/health/xeris-boosts-revenue-forecast-to-202-million-amidst-triple-digit-drug-sales-surge-what-this-means-for-investors/
Comments
Post a Comment